CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

Harbour Investments Inc. reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.9% during the 4th ...

CRISPR Therapeutics AG (CRSP ... The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

CRISPR gene-editing technology offers curative potential for ... Other investors find them too volatile, with prices stagnating for long periods and then moving strongly up or down depending ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. CRISPR Therapeutics is expected to post a loss of $1.31 ...

For that to happen, scientists must show that they can get CRISPR into more types of cells in the body cheaply and easily. The technology would also be boosted if it could serve as a platform to ...